Boehringer dumps its $250M NASH drug; Bavarian Nordic sells PRV for $95M; GBT inks deal with Syros, gets $150M loan
→ Four years after Boehringer handed out a $250 million deal to get a NASH drug from Pharmaxis, they’re sweeping it out of the pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
